Skip to main content
. 2004 Jun;112(2):301–309. doi: 10.1111/j.1365-2567.2004.01859.x

Figure 4.

Figure 4

(a) CCL19-IgG2b-secreting J558 tumours suppress regional lymph node enlargement. Single cell suspensions of the presented lymph nodes were prepared and total cell numbers were counted. Data represent mean total cell numbers per lymph node ± SD (n = 5 mice per group). Numbers of mesenteric cells have been divided by 5. Experiment was performed in duplicate. (b) CCL19-IgG2b-secreting tumours decrease homing of lymphocytes into draining lymph nodes. Splenocytes from syngeneic donor animals were labelled with CFDA SE and injected intravenously into CCL19-IgG2b-secreting J558 tumour or parental J558 tumour-bearing mice on day 7, respectively. Representative results of independent experiments with five recipient animals each are shown. (c) increase of CD11b+CD11c+ DCs within the tumour mass of mice receiving CCL19-IgG2b-transfected tumour cells. Tumours of each group (untransfected J558 cells vs. J558-CCL19-IgG2b-secreting tumours) were harvested 7 days after tumour injection and analysed by FACS for the presence of infiltrated cells. (d) Distribution of infiltrated lymphocytes (CD3+ and B220+ cells) per mass of tumour. Comparison of parental J558 tumour cells vs. J558-CCL19-IgG2b-secreting tumour cells. Tumours of each group were harvested 7 days after tumour injection and analysed by FACS for the presence of infiltrated lymphocytes.